Shares of Zomedica Pharmaceuticals (NYSEMKT: ZOM) continued their recent rapid ascent on Tuesday. As of 11:33 a.m. EST, the veterinary health company’s stock price is up more than 40%.
Excitement may be building for the upcoming launch of Zomedica’s point-of-care diagnostic platform for pets on March 30. The company says its patented system can help detect thyroid and adrenal disease in cats and dogs.
“We set out to develop a product that could provide the accuracy of the reference lab and the convenience of point-of-care for the veterinary community,” Zomedica chief medical officer Stephanie Morley said in a November press release announcing the launch. “As a vet myself, I know the value of such a product to a veterinary practice.”